Header Logo
Keywords
Last Name
Institution
Announcement

You can now add alternative names! Click here to add other names that you've published under.

Connection

Donghoon Yoon to Humans

This is a "connection" page, showing publications Donghoon Yoon has written about Humans.

 
Connection Strength
 
 
 
0.147
 
  1. Divoky V, Song J, Horvathova M, Kralova B, Votavova H, Prchal JT, Yoon D. Delayed hemoglobin switching and perinatal neocytolysis in mice with gain-of-function erythropoietin receptor. J Mol Med (Berl). 2016 05; 94(5):597-608.
    View in: PubMed
    Score: 0.022
  2. Yoon D, Ponka P, Prchal JT. Hypoxia. 5. Hypoxia and hematopoiesis. Am J Physiol Cell Physiol. 2011 Jun; 300(6):C1215-22.
    View in: PubMed
    Score: 0.016
  3. Yoon D, Okhotin DV, Kim B, Okhotina Y, Okhotin DJ, Miasnikova GY, Sergueeva AI, Polyakova LA, Maslow A, Lee Y, Semenza GL, Prchal JT, Gordeuk VR. Increased size of solid organs in patients with Chuvash polycythemia and in mice with altered expression of HIF-1alpha and HIF-2alpha. J Mol Med (Berl). 2010 May; 88(5):523-30.
    View in: PubMed
    Score: 0.015
  4. Yoon D, Agarwal N, Prchal JT. Does erythropoietin promote tumor growth? Clin Cancer Res. 2008 Mar 15; 14(6):1920; author reply 1920-1.
    View in: PubMed
    Score: 0.013
  5. Jo S, Pearson E, Yoon D, Kim J, Park WM. Self-Assembly of Microstructured Protein Coatings with Programmable Functionality for Fluorescent Biosensors. ACS Appl Mater Interfaces. 2024 Nov 20; 16(46):63284-63294.
    View in: PubMed
    Score: 0.010
  6. McCrury M, Swafford K, Shuttleworth SL, Mehdi SH, Acharya B, Saha D, Naceanceno K, Byrum SD, Storey AJ, Xu YZ, Doshier C, Patel V, Post GR, De Loose A, Rodriguez A, Shultz LD, Zhan F, Yoon D, Frett B, Kendrick S. Bifunctional Inhibitor Reveals NEK2 as a Therapeutic Target and Regulator of Oncogenic Pathways in Lymphoma. Mol Cancer Ther. 2024 Mar 04; 23(3):316-329.
    View in: PubMed
    Score: 0.010
  7. Hildebrandt GC, Berno T, Gurule A, Mohan M, Yoon D, Salama M, Zangari M. Effect of low-dose bortezomib on bone formation in smouldering multiple myeloma. Br J Haematol. 2019 01; 184(2):308-310.
    View in: PubMed
    Score: 0.006
  8. Johann DJ, Steliga M, Shin IJ, Yoon D, Arnaoutakis K, Hutchins L, Liu M, Liem J, Walker K, Pereira A, Yang M, Jeffus SK, Peterson E, Xu J. Liquid biopsy and its role in an advanced clinical trial for lung cancer. Exp Biol Med (Maywood). 2018 02; 243(3):262-271.
    View in: PubMed
    Score: 0.006
  9. Mohan M, Samant RS, Yoon D, Buros AF, Branca A, Montgomery CO, Nicholas R, Suva LJ, Morello R, Thanendrarajan S, Schinke C, Yaccoby S, van Rhee F, Davies FE, Morgan GJ, Zangari M. Extensive Remineralization of Large Pelvic Lytic Lesions Following Total Therapy Treatment in Patients With Multiple Myeloma. J Bone Miner Res. 2017 Jun; 32(6):1261-1266.
    View in: PubMed
    Score: 0.006
  10. Song J, Yoon D, Christensen RD, Horvathova M, Thiagarajan P, Prchal JT. HIF-mediated increased ROS from reduced mitophagy and decreased catalase causes neocytolysis. J Mol Med (Berl). 2015 Aug; 93(8):857-66.
    View in: PubMed
    Score: 0.005
  11. Zangari M, Berno T, Yang Y, Zeng M, Xu H, Pappas L, Tricot G, Kamalakar A, Yoon D, Suva LJ. Parathyroid hormone receptor mediates the anti-myeloma effect of proteasome inhibitors. Bone. 2014 Apr; 61:39-43.
    View in: PubMed
    Score: 0.005
  12. Tomasic NL, Piterkova L, Huff C, Bilic E, Yoon D, Miasnikova GY, Sergueeva AI, Niu X, Nekhai S, Gordeuk V, Prchal JT. The phenotype of polycythemia due to Croatian homozygous VHL (571C>G:H191D) mutation is different from that of Chuvash polycythemia (VHL 598C>T:R200W). Haematologica. 2013 Apr; 98(4):560-7.
    View in: PubMed
    Score: 0.005
  13. McClain DA, Abuelgasim KA, Nouraie M, Salomon-Andonie J, Niu X, Miasnikova G, Polyakova LA, Sergueeva A, Okhotin DJ, Cherqaoui R, Okhotin D, Cox JE, Swierczek S, Song J, Simon MC, Huang J, Simcox JA, Yoon D, Prchal JT, Gordeuk VR. Decreased serum glucose and glycosylated hemoglobin levels in patients with Chuvash polycythemia: a role for HIF in glucose metabolism. J Mol Med (Berl). 2013 Jan; 91(1):59-67.
    View in: PubMed
    Score: 0.004
  14. Swierczek SI, Yoon D, Bellann?-Chantelot C, Kim SJ, Saint-Martin C, Delhommeau F, Najman A, Prchal JT. Extent of hematopoietic involvement by TET2 mutations in JAK2V6?7F polycythemia vera. Haematologica. 2011 May; 96(5):775-8.
    View in: PubMed
    Score: 0.004
  15. Perrotta S, Cucciolla V, Ferraro M, Ronzoni L, Tramontano A, Rossi F, Scudieri AC, Borriello A, Roberti D, Nobili B, Cappellini MD, Oliva A, Amendola G, Migliaccio AR, Mancuso P, Martin-Padura I, Bertolini F, Yoon D, Prchal JT, Della Ragione F. EPO receptor gain-of-function causes hereditary polycythemia, alters CD34 cell differentiation and increases circulating endothelial precursors. PLoS One. 2010 Aug 05; 5(8):e12015.
    View in: PubMed
    Score: 0.004
  16. Bruchova-Votavova H, Yoon D, Prchal JT. miR-451 enhances erythroid differentiation in K562 cells. Leuk Lymphoma. 2010 Apr; 51(4):686-93.
    View in: PubMed
    Score: 0.004
  17. Bruchova H, Yoon D, Agarwal AM, Swierczek S, Prchal JT. Erythropoiesis in polycythemia vera is hyper-proliferative and has accelerated maturation. Blood Cells Mol Dis. 2009 Jul-Aug; 43(1):81-7.
    View in: PubMed
    Score: 0.003
  18. Bruchova H, Yoon D, Agarwal AM, Mendell J, Prchal JT. Regulated expression of microRNAs in normal and polycythemia vera erythropoiesis. Exp Hematol. 2007 Nov; 35(11):1657-67.
    View in: PubMed
    Score: 0.003
  19. Gaikwad A, Verstovsek S, Yoon D, Chang KT, Manshouri T, Nussenzveig R, Cortes J, Vainchenker W, Prchal JT. Imatinib effect on growth and signal transduction in polycythemia vera. Exp Hematol. 2007 Jun; 35(6):931-8.
    View in: PubMed
    Score: 0.003
  20. Mnjoyan Z, Yoon D, Li J, Delhommeau F, Afshar-Kharghan V. The effect of the JAK2 V617F mutation on PRV-1 expression. Haematologica. 2006 Mar; 91(3):411-2.
    View in: PubMed
    Score: 0.003
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.